Gain Therapeutics, Inc. (GANX) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 7 institutional investors hold a position in Gain Therapeutics, Inc. (NASDAQ:GANX).

• The percentage of Gain Therapeutics owned by institutions changed from 13.4% in September 2025 to 4.1% in December 2025, marking a slight down trend.
• Quarterly data indicates a 26.35% shift in institutional share volume, and the annual owner count reflects a decrease of 72.00%.
• Of these 7 institutional investors, 6 increased their holdings in Gain Therapeutics, while 1 of them reduced positions, and 0 investors maintained their exposure.
• This class of investors increased its holdings in Gain Therapeutics to 1.30Mn shares for the 13F-cycle ending December 2025, up by 271.07K shares quarter on quarter, and down 668.48K shares year over year.
• The top institutional stake in Gain Therapeutics as of December 31, 2025 belongs to VANGUARD GROUP INC, which owns 569.90K shares, or 1.79% of the company.
• Among the most significant buyers of Gain Therapeutics during December 2025 were Cambridge Investment Research Advisors, Inc. (250.00K), VANGUARD GROUP INC (35.55K), Oliver Luxxe Assets LLC (20.25K), Apollon Wealth Management, LLC (19.82K), BENEDICT FINANCIAL ADVISORS INC (3.00K).
• Leading sellers of Gain Therapeutics stock in December 2025 included UBS Group AG (59.56K).
• The top 7 institutional holders of Gain Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (569.90K), Cambridge Investment Research Advisors, Inc. (568.64K), UBS Group AG (81.12K), BENEDICT FINANCIAL ADVISORS INC (38.00K), Oliver Luxxe Assets LLC (20.25K), Apollon Wealth Management, LLC (19.82K), FNY Investment Advisers, LLC (2.00K).